CHS INTERNATIONAL RESEARCH LTD 

 
Biomedical Research/Anti-aging research/Galatamine
 
Aging research
Pharmaceutical grade human growth hormone (HGH, injection)
Pharmaceutical grade IGF 1LR3(injection)
Pharmaceutical grade rhTPO (injection)
Pharmaceutical grade Natural Galatamine (>98%, 50% purity)

Pharmaceutical Galatamine(>98%, 50% purity)

 

For medical research only

Not approved by FDA for human consumption in USA

wholesale price list

Item # mg/unit price per mg price FOB orange, CA 
GL10
GL
GL
GL
Retail price list
Item # mg/Unite price per mg price FOB  shipping
GL $450.00 $45.00
GL $295.99 $295.99
GL $289.99 $5,799.98
$259.99 $12,999.50
plus $80.00 per shipment charge
Please e-mail us your question and request. 
 

This is an imported and 100% natural extract of Galantamine hydrobromide from Lycoris radiata.  We market  this natural extract (high purity) for the pharmaceutical industry, the research institutes and for the nutrition product industry (low purity).

Galantamine hydrobromide, a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide. It has an empirical formula of C17H21NO3•HBr and a molecular weight of 368.27. Galantamine hydrobromide is a white to almost white powder and is sparingly soluble in water. The structural formula for galantamine hydrobromide is:

Image from Drug Label Content

Mechanism of Action

Although the etiology of cognitive impairment in Alzheimer's disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease. The degree of this cholinergic loss has been correlated with degree of cognitive impairment and density of amyloid plaques (a neuropathological hallmark of Alzheimer's disease).

Galantamine, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase. While the precise mechanism of galantamine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this mechanism is correct, galantamine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that galantamine alters the course of the underlying dementing process.

A Surprise Discovery

In the early 1990’s Janssen pharmaceuticals (in conjunction with Johnson and Johnson) sought a drug to improve the cognitive ability of Alzheimer’s patients. They had heard of the claims that an extract from the common snowdrop plant had long been used for improving memory in eastern European herbal lore. They successfully created a synthetic version of this extract and proved in experiments for the Food and Drug Administration that indeed the extract known as galantamine improved the memory of those ravaged by the disease (US Patent No. 4,663,318). In their studies they also noted an odd “side effect,” namely that those in the study reported significantly more dreams and enhanced dream recall.

This “side effect” excited dream researchers who further studied the natural plant extract and found that indeed several plants including the red spider lily and the common snowdrop had the effect of lengthening dreams, making them more vivid and easier to recall in the morning. Those taking galantamine at bedtime reported more dreams and described themselves as being “totally engrossed in a movie or fiction where on one level you really feel as if you are there and on another level realizing you dream.” A particularly interesting effect is that someone can wake up from a galantamine dream in the middle of the night and choose to go back to sleep and reenter the same dreamscape again.

The commercial names of synthetic Galantamine hydrobromide are:

RAZADYNEtm ER Extended-Release Capsules and RAZADYNEtm Tablets are manufactured by:
JOLLC, Gurabo, Puerto Rico or
Janssen-Cilag SpA Latina, Italy

RAZADYNEtm Oral Solution is manufactured by:
Janssen Pharmaceutica N.V.
Beerse, Belgium

RAZADYNEtm ER Extended-Release Capsules and RAZADYNEtm Tablets and Oral Solution are distributed by:

Ortho-McNeil Neurologics, Inc.
Titusville, NJ 08560